Elsevier

The Lancet

Volume 338, Issue 8776, 9 November 1991, Pages 1174-1175
The Lancet

SHORT REPORTS
Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine

https://doi.org/10.1016/0140-6736(91)92034-YGet rights and content

Abstract

2 patients had neurological symptoms and signs, with evidence of central-nervous-system demyelination, 6 weeks after administration of recombinant hepatitis B vaccine. 1 had known multiple sclerosis but the other had no history of neurological disease; both had HLA haplotypes DR2 and B7, which are associated with multiple sclerosis. A causal link between vaccination and demyelination cannot be established from these 2 case-reports, but the time interval would fit a proposed immunological mechanism.

References (5)

There are more references available in the full text version of this article.

Cited by (168)

  • Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity

    2022, Multiple Sclerosis and Related Disorders
    Citation Excerpt :

    Though exceedingly safe in the general population, vaccination against HBV has raised concerns regarding its potential to cause MS and exacerbate its symptoms. These concerns were largely driven by early reports of patients with MS and otherwise healthy adults developing demyelinating lesions after vaccination (Herroelen et al., 1991; Tourbah et al., 1999). However, subsequent case-control studies failed to establish a link between HBV vaccination and elevated MS risk in adolescents and adults (DeStefano et al., 2003; Mikaeloff et al., 2007; Ascherio et al., 2001).

  • General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis

    2022, Vaccine
    Citation Excerpt :

    There has been a great deal of uncertainty among both physicians and patients about the risk–benefit ratio of vaccination in MS [15]. There have been reports of various neurological disorders after vaccination, such as encephalomyelitis after active influenza vaccination [16] and similar disorders after mumps, measles and rubella vaccination [17] in patients with and without MS. Disease progression or new-onset demyelinating lesions have been observed after a hepatitis B vaccination [18,19]. However, no increased risk of CNS manifestations was found for any of these vaccinations in various case-control studies with MS patients and healthy ones [20] or with regard to other autoimmune diseases [21].

  • Safety of Sinopharm vaccine for people with Multiple Sclerosis: Study of adverse reactions and disease activity

    2022, Multiple Sclerosis and Related Disorders
    Citation Excerpt :

    Münz et al., 2009) Past research studies have focused on the risk of MS exacerbations and demyelinating disease after immunization against hepatitis B (Herroelen, de Keyser and Ebinger, 1991) (Tourbah et al., 1999). A study by Langer-Gould showed that Influenza vaccination might increase the risk for developing CNS demyelinating disorders up to one month after immunization.

  • Vaccine development

    2019, Genomic and Precision Medicine: Infectious and Inflammatory Disease
  • Vaccines and the risk of acute disseminated encephalomyelitis

    2018, Vaccine
    Citation Excerpt :

    Our results are also different from another analysis conducted in France which found that the number of notified cases that occurred within 2 months after HepB vaccination was higher than expected [16]. There have been some case reports of central nervous system demyelination within a few weeks after the HepB vaccination, but as their authors recognize, these reports cannot demonstrate a causal or triggering association [17,18]. Influenza vaccine is another commonly administered to people.

  • Hepatitis B and pregnancy. Part 1. Thirteen practical issues in antenatal period

    2016, Journal de Gynecologie Obstetrique et Biologie de la Reproduction
View all citing articles on Scopus
View full text